Abbott yanks apps for psoriasis drug; R&D company lays off 49;

 @FierceBiotech: Shulman: Best biotech stocks to own. Story | Follow @FierceBiotech

> Abbott Laboratories has yanked applications in the U.S. and Europe for an experimental psoriasis drug after regulators made it clear that they wanted to see more data on the treatment before they offer a green light on sales. The new info needed may require new trials. Reuters says that the company made it clear in filings that it will review its plans for briakinumab and may resubmit the apps later. Report

> Taconic, a company that breeds rodents for drug research, says that a contraction in the biopharma research space has forced it to lay off 49 workers, most in New York. Story

> On Wednesday an FDA panel rejected a new enzyme replacement therapy from Eli Lilly. A majority of the experts says that the company failed to demonstrate significant efficacy with the data that was submitted. Report

> Cumberland Pharma says the FDA has approved a new formulation for its injectable therapy for acetaminophen poisoning. Item

> Orexigen is closing in on its PDUFA date. Article

And Finally... To help prevent a future bird flu pandemic, researchers in the UK created chickens genetically modified to prevent them from spreading the flu. Release